Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | OPGN | Series E Convertible Preferred Stock | Purchase | $150K | +150K | +37.5% | $1.00 | 550K | Apr 23, 2024 | Common Stock | 3.6M | Direct | F1, F2, F3, F4 |
Id | Content |
---|---|
F1 | On March 25, 2024, David E. Lazar (the "Reporting Person") and OpGen, Inc. (the "Company"), entered into a securies purchase agreement pursuant to which the Reporting Person will acquire an aggregate of 3,000,000 shares of the Company's Series E Convertible Preferred Stock (the "Series E Preferred Stock") at a price of $1.00 per share. Each share of Series E Preferred Stock is convertible into 24 shares of the Company's Common Stock at any time, subject to certain ownership limitations. The initial closing took place on March 25, 2024, whereby the Reporting Person acquired 200,000 shares of Series E Preferred Stock for a total purchase price of $200,000. On April 23, 2024, the Reporting Person acquired an additional 150,000 shares of Series E Preferred Stock for a total purchase price of $150,000. The Reporting Person will acquire additional shares of Series E Preferred Stock at subsequent closings, subject to certain conditions being satisfied. |
F2 | The shares of Series E Preferred Stock are convertible at the option of the Reporting Person for no additional consideration. |
F3 | The Series E Preferred Stock is perpetual and therefore has no expiration date. |
F4 | The Reporting Person's Form 4 filed on April 13, 2024 inadvertently included as the number of derivative securities beneficially owned the number of shares of the Company's Common Stock that would be owned following the conversion of the Series E Preferred Stock. The number of derivative securities beneficially owned is correctly reported in this Form 4. |